Response to trametinib in a nonsmall cell lung cancer patient with osimertinib resistance harboring GNAS R201C and R201H mutations: a case report

Osimertinib, an orally administered third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is widely approved for the first-line and second-line treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. However, the rapid development of osimertinib re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, You, Zhou, Chao, Chen, Zhonghai, Zhao, Xiaokai, Sun, Yonghua, Li, Jieyi, Gong, Ziying, Zhang, Daoyun, Huang, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481290/
https://www.ncbi.nlm.nih.gov/pubmed/35946511
http://dx.doi.org/10.1097/CAD.0000000000001342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481290/
https://www.ncbi.nlm.nih.gov/pubmed/35946511
http://dx.doi.org/10.1097/CAD.0000000000001342

Ejemplares similares